Amphastar Pharmaceuticals(DE:29A)
€25.65-0.35 (-1.35%)
DE:29A
Amphastar Pharmaceuticals financials statements
€25.65
At close:-0.35 (-1.35%)
Amphastar Pharmaceuticals (29A) Ratios
2 Followers
Amphastar Pharmaceuticals Ratios
DE:29A's free cash flow for Q3 2026 was $33.36M. For the 2026 fiscal year, DE:29A's free cash flow was decreased by $-9.94M and operating cash flow was $43.30M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.02 | 3.07 | 2.17 | 3.99 | 3.06 |
| Quick Ratio | 2.90 | 2.19 | 1.70 | 2.90 | 2.17 |
| Cash Ratio | 1.08 | 0.87 | 0.64 | 1.65 | 1.22 |
| Solvency Ratio | 0.19 | 0.26 | 0.21 | 0.56 | 0.39 |
| Operating Cash Flow Ratio | 0.99 | 1.23 | 0.81 | 0.94 | 0.94 |
| Short-Term Operating Cash Flow Coverage | 95.13 | 911.91 | 420.88 | 29.28 | 44.50 |
| Net Current Asset Value | $ -204.48M | $ -311.10M | $ -383.89M | $ 164.99M | $ 92.11M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.40 | 0.41 | 0.41 | 0.14 | 0.16 |
| Debt-to-Equity Ratio | 0.83 | 0.89 | 0.98 | 0.19 | 0.23 |
| Debt-to-Capital Ratio | 0.45 | 0.47 | 0.49 | 0.16 | 0.19 |
| Long-Term Debt-to-Capital Ratio | 0.44 | 0.45 | 0.48 | 0.12 | 0.14 |
| Financial Leverage Ratio | 2.07 | 2.15 | 2.37 | 1.40 | 1.51 |
| Debt Service Coverage Ratio | 6.89 | 8.10 | 7.55 | 25.08 | 29.45 |
| Interest Coverage Ratio | 5.51 | 6.77 | 7.25 | 58.23 | 78.97 |
| Debt to Market Cap | 0.49 | 0.33 | 0.20 | 0.06 | 0.07 |
| Interest Debt Per Share | 14.58 | 14.06 | 13.48 | 2.15 | 2.21 |
| Net Debt to EBITDA | 2.29 | 1.80 | 1.99 | -0.37 | -0.19 |
| Profitability Margins | |||||
| Gross Profit Margin | 49.46% | 51.08% | 54.49% | 49.87% | 45.63% |
| EBIT Margin | 20.71% | 30.07% | 30.81% | 23.63% | 19.42% |
| EBITDA Margin | 29.49% | 37.89% | 37.29% | 29.29% | 25.48% |
| Operating Profit Margin | 19.50% | 28.06% | 30.57% | 21.54% | 15.96% |
| Pretax Profit Margin | 17.17% | 25.85% | 26.28% | 23.02% | 19.17% |
| Net Profit Margin | 13.63% | 21.79% | 21.34% | 18.31% | 14.19% |
| Continuous Operations Profit Margin | 13.63% | 21.79% | 21.34% | 18.31% | 14.46% |
| Net Income Per EBT | 79.35% | 84.32% | 81.21% | 79.56% | 74.01% |
| EBT Per EBIT | 88.05% | 92.10% | 85.98% | 106.85% | 120.10% |
| Return on Assets (ROA) | 6.02% | 10.11% | 9.09% | 12.32% | 9.25% |
| Return on Equity (ROE) | 12.44% | 21.78% | 21.51% | 17.29% | 13.94% |
| Return on Capital Employed (ROCE) | 9.54% | 14.63% | 15.30% | 16.61% | 12.31% |
| Return on Invested Capital (ROIC) | 7.52% | 12.28% | 12.38% | 13.09% | 9.20% |
| Return on Tangible Assets | 9.23% | 16.17% | 15.29% | 12.97% | 9.82% |
| Earnings Yield | 7.84% | 8.87% | 4.61% | 6.72% | 5.58% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.01 | 5.30 | 5.58 | 5.62 | 5.56 |
| Payables Turnover | 11.16 | 11.74 | 11.53 | 12.20 | 10.72 |
| Inventory Turnover | 2.06 | 2.33 | 2.77 | 2.41 | 2.56 |
| Fixed Asset Turnover | 2.04 | 2.12 | 2.04 | 1.89 | 1.61 |
| Asset Turnover | 0.44 | 0.46 | 0.43 | 0.67 | 0.65 |
| Working Capital Turnover Ratio | 1.72 | 2.34 | 2.35 | 2.00 | 2.29 |
| Cash Conversion Cycle | 217.55 | 194.43 | 165.46 | 186.20 | 173.95 |
| Days of Sales Outstanding | 72.79 | 68.83 | 65.40 | 64.96 | 65.70 |
| Days of Inventory Outstanding | 177.46 | 156.70 | 131.72 | 151.16 | 142.31 |
| Days of Payables Outstanding | 32.70 | 31.10 | 31.66 | 29.92 | 34.06 |
| Operating Cycle | 250.25 | 225.53 | 197.12 | 216.11 | 208.02 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 3.34 | 4.41 | 3.80 | 1.84 | 2.05 |
| Free Cash Flow Per Share | 2.59 | 3.56 | 3.01 | 1.34 | 1.48 |
| Dividend Paid and CapEx Coverage Ratio | 4.48 | 5.20 | 4.81 | 3.71 | 3.57 |
| Capital Expenditure Coverage Ratio | 4.48 | 5.20 | 4.81 | 3.71 | 3.57 |
| Operating Cash Flow Coverage Ratio | 0.24 | 0.33 | 0.29 | 0.87 | 0.94 |
| Operating Cash Flow to Sales Ratio | 0.22 | 0.29 | 0.28 | 0.18 | 0.22 |
| Free Cash Flow Yield | 9.68% | 9.58% | 4.87% | 4.79% | 6.34% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 12.75 | 11.27 | 21.70 | 14.89 | 17.91 |
| Price-to-Sales (P/S) Ratio | 1.74 | 2.46 | 4.63 | 2.73 | 2.54 |
| Price-to-Book (P/B) Ratio | 1.59 | 2.46 | 4.67 | 2.57 | 2.50 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 10.33 | 10.43 | 20.54 | 20.88 | 15.77 |
| Price-to-Operating Cash Flow Ratio | 8.02 | 8.43 | 16.27 | 15.25 | 11.36 |
| Price-to-Earnings Growth (PEG) Ratio | -0.35 | 0.73 | 0.42 | 0.33 | 0.00 |
| Enterprise Value Multiple | 8.18 | 8.28 | 14.42 | 8.94 | 9.78 |
| Enterprise Value | 1.74B | 2.30B | 3.46B | 1.31B | 1.09B |
| EV to EBITDA | 8.18 | 8.28 | 14.42 | 8.94 | 9.78 |
| EV to Sales | 2.41 | 3.14 | 5.38 | 2.62 | 2.49 |
| EV to Free Cash Flow | 14.33 | 13.33 | 23.84 | 20.06 | 15.47 |
| EV to Operating Cash Flow | 11.13 | 10.77 | 18.88 | 14.65 | 11.13 |
| Tangible Book Value Per Share | 4.77 | 2.92 | 0.54 | 10.12 | 8.51 |
| Shareholders’ Equity Per Share | 16.88 | 15.12 | 13.25 | 10.89 | 9.33 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.21 | 0.16 | 0.19 | 0.20 | 0.25 |
| Revenue Per Share | 15.40 | 15.11 | 13.35 | 10.28 | 9.16 |
| Net Income Per Share | 2.10 | 3.29 | 2.85 | 1.88 | 1.30 |
| Tax Burden | 0.79 | 0.84 | 0.81 | 0.80 | 0.74 |
| Interest Burden | 0.83 | 0.86 | 0.85 | 0.97 | 0.99 |
| Research & Development to Revenue | 0.12 | 0.10 | 0.11 | 0.15 | 0.14 |
| SG&A to Revenue | 0.18 | 0.13 | 0.08 | 0.09 | 0.12 |
| Stock-Based Compensation to Revenue | 0.04 | 0.03 | 0.03 | 0.04 | 0.04 |
| Income Quality | 1.59 | 1.34 | 1.33 | 0.98 | 1.55 |
Currency in USD
